drugset
Drugs / Beriplex
last change Mar 2026 re-read 3 minutes ago

Beriplex

also known as Confidex
Investigated by
CSL Behring · Boehringer Ingelheim · University Medical Center Groningen

Trials 2

today NCT02463591 · Ph 2 NCT00803101 · Ph 3
2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT02463591 Jan 2015 → Jul 2016 — University Medical Center Groningen Unknown No outcome recorded
Phase 31 trial · 1 met primary
Phase 3 NCT00803101 Feb 2009 → Nov 2012 — CSL Behring Completed Met primary

Press releases naming this drug 1 release

DateIssuerRelease
2012-07-06 CSL Behring CSL Behring Launches New Beriplex® P/N Dosing Calculator App for Healthcare Professionals on the Move csl.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as Beriplex ClinicalTrials.gov intervention name — accepted as the source's own label NCT00803101 ↗
1

NCT02463591 ↗
Known as Confidex “vitamin K concomitant with a single dose of either 4F-PCC (Beriplex/Kcentra/Confidex; CSL Behring, Marburg, Germany) or plasma” PMID 25728933 ↗ Feb 2015
Action Restore “restoration of vitamin K-dependent factors” PMID 41910938 ↗ Mar 2026
Route Intravenous “Intravenous infusion” NCT00803101 ↗